Objective: To examine efficacy and safety of adjunctive guanfacine extended release (GXR) on morning and evening ADHD symptoms using the Conners’ Global Index–Parent (CGI-P) and Before-School Functioning Questionnaire (BSFQ). Method: Participants 6 to 17 years with ADHD (N = 461) and suboptimal psychostimulant response were maintained on current psychostimulants and randomized to dose-optimized GXR (≤4 mg/d) in the morning (GXR AM) or evening (GXR PM), or placebo. Results: CGI-P scores improved with GXR (morning assessment, GXR AM, placebo-adjusted least squares [LS] mean = -1.7, GXR PM = -2.6; evening assessment, GXR AM = -2.4, GXR PM = -3.0; all ps < .01). Parent-rated BSFQ scores reflected improved morning functioning with GXR (GXR AM, placebo-adjusted LS mean = -5.1; GXR PM = -4.7; both ps < .01). Most adverse events were mild or moderate. Conclusion: Adjunctive GXR AM or GXR PM was associated with improvements in morning and evening ADHD symptoms in children and adolescents.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
2.
BiedermanJ.FaraoneS. V. (2005). Attention-deficit hyperactivity disorder. Lancet, 366, 237-248.
3.
BiedermanJ.LopezF. A.BoellnerS. W.ChandlerM. C. (2002). A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics, 110, 258-266.
4.
BiedermanJ.MelmedR. D.PatelA.McBurnettK.KonowJ.LyneA.SchererN. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121, e73-e84.
5.
BiedermanJ.MonuteauxM. C.MickE.SpencerT.WilensT. E.SilvaJ. M.. . .FaraoneS. V. (2006). Young adult outcome of attention deficit hyperactivity disorder: A controlled 10-year follow-up study. Psychological Medicine, 36, 167-179.
6.
BlockS. L.KelseyD.CouryD.LewisD.QuintanaH.SuttonV.. . .SumnerC. (2009). Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: Comparison of morning and evening dosing. Clinical Pediatrics (Phila), 48, 723-733.
7.
BuitelaarJ.MedoriR. (2010). Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: A review of the potential benefits of long-acting stimulants. European Child & Adolescent Psychiatry, 19, 325-340.
8.
CoghillD.SoutulloC.d’AubuissonC.PreussU.LindbackT.SilverbergM.BuitelaarJ. (2008). Impact of attention-deficit/hyperactivity disorder on the patient and family: Results from a European survey. Child and Adolescent Psychiatry and Mental Health, 2, 31.
KesslerR. C.BerglundP.DemlerO.JinR.MerikangasK. R.WaltersE. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593-602.
12.
McGoughJ. J.BiedermanJ.WigalS. B.LopezF. A.McCrackenJ. T.SpencerT.. . .TullochS. J. (2005). Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 530-538.
13.
NewcornJ. H.ClerkinS.SchulzK. P.HalperinJ. M. (2011). α2-Adrenergic agonists: Clonidine and guanfacine. In MartinA.ScahillL.KratochvilC. (Eds.), Pediatric psychopharmacology: Principles and practice (pp. 263-274). New York, NY: Oxford University Press.
14.
PliszkaS. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 894-921.
15.
PolanczykG.de LimaM. S.HortaB. L.BiedermanJ.RohdeL. A. (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164, 942-948.
16.
SalleeF. R.McGoughJ.WigalT.DonahueJ.LyneA.BiedermanJ. (2009). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 155-165.
17.
SpencerT. J.GreenbaumM.GinsbergL. D.MurphyW. R. (2009). Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19, 501-510.
18.
SteinM.YouchaS.WhiteC.EnrightG.RubinJ. (2011, May12-14). Efficacy of guanfacine extended release, administered in the morning or evening in the treatment of children with attention-deficit/hyperactivity disorder. Poster presented at: The 66th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA.
19.
WeissM.TannockR.KratochvilC.DunnD.Velez-BorrasJ.ThomasonC.. . .AllenA. J. (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 647-655.
20.
WhalenC. K.HenkerB.JamnerL. D.IshikawaS. S.FloroJ. N.SwindleR.. . .JohnstonJ. A. (2006). Toward mapping daily challenges of living with ADHD: Maternal and child perspectives using electronic diaries. Journal of Abnormal Child Psychology, 34, 115-130.
21.
WilensT. E.BiedermanJ.BrownS.TanguayS.MonuteauxM. C.BlakeC.SpencerT. J. (2002). Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 262-268.
22.
WilensT. E.BuksteinO.BramsM.CutlerA. J.ChildressA.RuginoT.. . .YouchaS. (2012). A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51, 74-85.
23.
WilensT. E.HammernessP.MartelonM.BrodziakK.UtzingerL.WongP. (2010a). A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 71, 548-556.
24.
WilensT. E.LyneA.YouchaS. (2010b, June14-17). A study of the coadministration of guanfacine extended release and a psychostimulant for the treatment of attention-deficit/hyperactivity disorder: Design and rationale. Poster presented at: New Clinical Drug Evaluation Unit 50th Annual Meeting, Boca Raton, FL.
